Fosrenol (Lanthanum Carbonate Hydrate) - Summary

FOSRENOL SUMMARY

FOSRENOL® (foss-wren-all)
(Lanthanum Carbonate) 250 mg and 500 mg Chewable Tablets.

FOSRENOL® contains lanthanum carbonate (2:3) hydrate with molecular formula La₂(CO₃)₃xH₂O (on average x=4-5 moles of water) and molecular weight 457.

FOSRENOL® is indicated to reduce serum phosphate in patients with end stage renal disease.

FOSRENOL NEWS HIGHLIGHTS

Published Studies Related to Fosrenol (Lanthanum Carbonate)

Effects of lanthanum carbonate on the absorption and oral bioavailability of ciprofloxacin. [2007.11]

Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy. [2007.02]

Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. [2006.08]

Absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate. [2006.07]

Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. [2006.03]

more>>

Clinical Trials Related to Fosrenol (Lanthanum Carbonate)

Conversion From Standard Phosphate Binder Therapy to Fosrenol® (Lanthanum Carbonate) in Chronic Kidney Disease Stage 5 [Terminated]

Efficacy and Safety of Lanthanum Carbonate in Reducing Serum Phosphorus Levels in Subjects With Stage 3 and 4 Chronic Kidney Disease [Completed]

Chewed vs. Crushed Lanthanum Carbonate in Hemodialysis Patients [Recruiting]

Head to Head Study Against Sevelamer Hydrochloride [Active, not recruiting]

Long Term Treatment of End Stage Renal Disease Patients With Lanthanum Carbonate (Fosrenol) [Recruiting]

more>>